⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899739 | 0.79 | — | — | |
| SCHEMBL20627945 | 0.67 | — | — | |
| SCHEMBL18940953 | 0.63 | — | — | |
| SCHEMBL23279351 | 0.61 | — | — | |
| SCHEMBL8436850 | 0.53 | — | — | |
| SCHEMBL13779641 | 0.50 | — | — | |
| SCHEMBL9881076 | 0.49 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL21906686 | 0.49 | — | — | |
| SCHEMBL20224242 | 0.49 | — | — | |
| SCHEMBL14275653 | 0.48 | GABRP (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1704139-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RAR y RETINOID RECEPTORS | Allergan, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-6936636-B2 | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| WO-2005066116-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RARϜ RETINOID RECEPTORS | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
| US-20050004213-A1 | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. | 2005-01-06 | — | — | US | disclosed |